Review of Clinical Evidences: Weekly growth hormone Somatrogon in management of pGHDEvent

Speciality: Endocrinology

Description:

A warm welcome to all the medical professionals in this interesting session on review of clinical evidences:weekly growth hormone smatrogon in management of pGHDEvent.
Smatrogon, a long-acting recombinant human growth hormone, has shown promising clinical evidence in the treatment of pediatric growth hormone deficiency (pGHD). Studies indicate that weekly administration of Smatrogon is not only effective but also well-tolerated in promoting growth in children with pGHD. Compared to daily growth hormone injections, Smatrogon offers a more convenient treatment regimen, leading to improved adherence without compromising efficacy. Clinical trials have demonstrated comparable outcomes in height velocity, insulin-like growth factor (IGF-1) levels, and overall safety profile when administered weekly versus traditional daily injections.
Moreover, the long-term use of Smatrogon has shown sustained growth outcomes over extended periods, providing a viable alternative for children with pGHD. Patients receiving the weekly Smatrogon treatment reported fewer adverse effects and an improved quality of life due to reduced injection frequency, making it a favorable option. Overall, the clinical evidence supports Smatrogon as a significant advancement in growth hormone therapy for pGHD, balancing efficacy, safety, and patient compliance.
 

See More Webinars @ Hidoc Webinars